New Method of Protection Against Pneumococcal Pneumonia

    VaxNewMo is developing pneumococcal conjugate vaccines to provide broader protection against more strains of bacteria that cause pneumococcal pneumonia. The company says its bioconjugation technology bypasses dependency on the synthetic chemistry techniques previously required to manufacture conjugate vaccines. The St. Louis startup has engineered E. coli to manufacture the pneumococcal conjugate vaccines. VaxNewMo says its method is faster, better and less expensive than traditional methods used by pharmaceutical companies.

    Related Posts

    Things to do in St. Louis

    • 1. Striking Power: Iconoclasm in Ancient Egypt. Read More
    • 2. How We See Materiality and Color Opens at Laumeier Sculpture Park. Read More
    • 3. Muny Memories. Read More
    Sign Up
    HEC-TV NewsLetter

    Playing Now

    • 07:00 | Conversations from Donald Danforth Plant Science Center
    • 08:00 | Books Presented by HEC Media
    • 08:30 | HEC Media Documentary
    • 09:00 | Frames
    • 10:30 | HEC Media Documentary